PReDicT测试指导抑郁患者抗抑郁治疗效果的随机对照试验方案
本研究为一项在五个欧洲国家开展的多中心、随机、双臂、开放标签的医疗器械临床研究,评估PReDicT测试指导抗抑郁治疗相比常规治疗能否加速治疗反应。主要结局是第8周时临床缓解(抑郁症状自评问卷基线评分下降≥50%)的患者比例,同时收集卫生经济学和可接受性数据。
要点
- PReDicT测试基于情感认知的早期变化预测抗抑郁治疗反应。
- 测试组在治疗1周(必要时2周)后检测,非反应者建议调整剂量或换药。
- 主要结局为第8周临床缓解率,同时评估成本效果和可接受性。
核心结论
- 本试验将检验PReDicT测试指导抗抑郁治疗选择的临床疗效、成本效果和可接受性。
研究设计与样本
- 随机、双臂、多中心、开放标签的医疗器械临床研究,在五个欧洲国家(英国、法国、西班牙、德国、荷兰)开展,纳入开始抗抑郁药物治疗的抑郁患者。
- 患者随机分为PReDicT测试指导治疗组(PReDicT组)或常规治疗组(TaU组)。
主要发现
- 既往研究表明抗抑郁药物可改变抑郁患者的情感认知细微指标(如面部表情评价),且这些认知效应在治疗早期出现并能预测后期临床反应。
关键数值与推荐
- PReDicT组在治疗1周(必要时2周)后完成PReDicT测试,若测试提示对治疗无反应,建议医生立即调整抗抑郁治疗(剂量增加或换用另一种药物)。
- TaU组按所在国家现行标准指南治疗。
- 主要结局为第8周时临床缓解的患者比例,缓解定义为Quick Inventory of Depressive Symptoms - Self-Rated问卷基线评分下降≥50%。
临床怎么用
- PReDicT测试若有效,可辅助医生在治疗早期识别可能无反应的患者并及时调整方案,从而加速治疗反应。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antidepressant medication is commonly used to treat depression. However, many patients do not respond to the first medication prescribed and improvements in symptoms are generally only detectable by clinicians 4-6 weeks after the medication has been initiated. As a result, there is often a long delay between the decision to initiate an antidepressant medication and the identification of an effective treatment regimen. Previous work has demonstrated that antidepressant medications alter subtle measures of affective cognition in depressed patients, such as the appraisal of facial expression. Furthermore, these cognitive effects of antidepressants are apparent early in the course of treatment and can also predict later clinical response. This trial will assess whether an electronic test of affective cognition and symptoms (the Predicting Response to Depression Treatment Test; PReDicT Test) can be used to guide antidepressant treatment in depressed patients and, therefore, hasten treatment response compared to a control group of patients treated as usual. METHODS/DESIGN: The study is a randomised, two-arm, multi-centre, open-label, clinical investigation of a medical device, the PReDicT Test. It will be conducted in five European countries (UK, France, Spain, Germany and the Netherlands) in depressed patients who are commencing antidepressant medication. Patients will be randomised to treatment guided by the PReDicT Test (PReDicT arm) or to Treatment as Usual (TaU arm). Patients in the TaU arm will be treated as per current standard guidelines in their particular country. Patients in the PReDicT arm will complete the PReDicT Test after 1 (and if necessary, 2) weeks of treatment. If the test indicates non-response to the treatment, physicians will be advised to immediately alter the patient's antidepressant therapy by dose escalation or switching to another compound. The primary outcome of the study is the proportion of patients showing a clinical response (defined as 50% or greater decrease in baseline scores of depression measured using the Quick Inventory of Depressive Symptoms - Self-Rated questionnaire) at week 8. Health economic and acceptability data will also be collected and analysed. DISCUSSION: This trial will test the clinical efficacy, cost-effectiveness and acceptability of using the novel PReDicT Test to guide antidepressant treatment selection in depressed patients. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02790970 . Registered on 30 March 2016.
引用
- Kingslake J, Dias R, Dawson GR, et al. The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial. Trials. 2017. PMID: 29169399. doi:10.1186/s13063-017-2247-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。